| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 961915 | Journal of Health Economics | 2010 | 7 Pages |
Abstract
To promote stockpiling of anti-viral drugs by non-government organizations such as hospitals, drug manufacturers have introduced Manufacturer Reserve Programs which, for an annual fee, provide the right to buy in the event of a severe outbreak of influenza. We show that these programs enhance drug manufacturer profits but could either increase or decrease the amount of pre-pandemic stockpiling of anti-viral drugs.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Joseph E. Jr., Edbert B. Hsu,